Beginning in 2023, all new content from the editorial teams of Practical Cardiology, @EndocrineNetwrk, & @RheumatologyNet will be hosted on @MDMagazine.
Learn how the merger helps us achieve our goal of improving the management of cardiovascular disease:
https://t.co/mSb8Hu5msu
Updated AHA/ACC guidelines for hypertrophic cardiomyopathy include a new emphasis on the roles of exercise and cardiac myosin inhibitors.
Learn more:
https://t.co/OyQcSOiglG
#Cardiology#Cardiomyopathy
🚨 We are just days away from our #PreACCChat with @APAC_Cardiology on April 1 from 8-9 PM ET ! 🚨
Check out our 10 questions and posting times to prepare for the evening and participate on Monday night!
#CardioTwitter#Cardiology#ACC24
Part 1:
🚨 We are 1 week away from our pre-ACC Tweet Chat with Academy of Physician Associates In Cardiology 🚨
Check back later this week for the full list of questions or tune in on April 1 from 8 to 9 PM ET to participate!
https://t.co/YrnGBuMwgw
#CardioTwitter#ACC24#ACC2024
🚨 We are 1 week away from our pre-ACC Tweet Chat with Academy of Physician Associates In Cardiology 🚨
Check back later this week for the full list of questions or tune in on April 1 from 8 to 9 PM ET to participate!
https://t.co/YrnGBuMwgw
#CardioTwitter#ACC24#ACC2024
🚨 We are 10 days away from our pre-ACC Tweet Chat with @APAC_Cardiology! 🚨
Join us on April 1 at 8 PM ET for a 10-question tweet chat discussing all things #ACC24, including the most anticipated sessions, pressing research needs, and more!
https://t.co/YrnGBuMwgw
#Cardiology
The FDA has approved the first oral antihypertensive agent with a new mechanism of action in more 30 years with the approval of aprocitentan (Tryvio; Idorsia Pharmaceuticals Ltd) for difficult-to-control hypertension.
Learn more:
https://t.co/slk3Zz0M8P
#FDANews#Hypertension
Last week, @HFSA published a scientific statement on cognitive impairment in #HeartFailure.
I was lucky enough to sit in on a conversation between lead co-authors (@EiranGorodeski/@ParagGoyalMD) and HFSA president @JamesCFangMD.
Clip below, link in next tweet for full video:
What are the top issues facing cardiology in 2024? DCRI's @SJGreene_md joins other leading experts to provide insights into key challenges and what can be done to overcome them: https://t.co/jWw4YJy24I
To commemorate the conclusion of #BlackHistoryMonth, HCPLive conducted a series of interviews with experts in diversity and equity in healthcare to address medicine's elephant in the room: how lacking clinical trial diversity impacts real-world care:
https://t.co/Oei153elfj
For American Heart Month, we asked 9 experts in cardiology for their perspective on the most prevalent issues facing the specialty today.
https://t.co/YM4kiA3doM
#Cardiology#CardiovascularDisease@DLBHATTMD @DrLaxmiMehta @HCPLiveCardiology @HCPLiveNews
Earlier this week, we spoke with @DLBHATTMD, of @MountSinaiHeart, about a recent publication in @ESC_Journals highlighting the need for greater in-hospital initiation and uptitration of GDMT in #HeartFailure.
https://t.co/vomzjm8Rtn
New research links maternal T1D to nearly all subtypes of congenital #heart defects, while overweight was associated only with certain defect types.
https://t.co/5N067clpSB
#Cardiotwitter
Positive topline data from SEQUOIA-HCM announced by @Cytokinetics, with statistically significant benefit on exercise capacity and in all 10 prespecified secondary endpoints.
Learn more:
https://t.co/6wXlSq77X4
#Cardiomyopathy#Cardiotwitter